RCA
PFE icon

Runnymede Capital Advisors’s Pfizer PFE Stock Holding History

Runnymede Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-197
Closed -$4.99K – 209
2025
Q1 		$4.99K Buy
197
+117
+146% +$3.06K ﹤0.01% 232
2024
Q4 		$2.12K Buy
+80
New +$2.17K ﹤0.01% 256

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Runnymede Capital Advisors's PFE Position: Q2 2025 in Review

Runnymede Capital Advisors sold out of Pfizer (PFE) in Q2 2025, closing a stake of 197 shares — an estimated $4.99K sold.

Runnymede Capital Advisors first reported a position in PFE in Q4 2024 and held it in 2 quarters. The position peaked at $4.99K in Q1 2025. 2,810 funds tracked by Wall St. Rank hold PFE as of Q2 2025.

  • Runnymede Capital Advisors reported no remaining Pfizer position as of Q2 2025 after selling out during the quarter.
  • Runnymede Capital Advisors sold 197 Pfizer shares in Q2 2025, an estimated $4.99K.
  • Runnymede Capital Advisors first reported a position in Pfizer in Q4 2024 and held it in 2 quarters.
  • Runnymede Capital Advisors's Pfizer position peaked at $4.99K in Q1 2025.
  • 2,810 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.

Based on Runnymede Capital Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.